Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

2931 and LX7101 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.
Selected Financial Data

 Consolidated Statements of Operations DataThree Months EndedDecember 31,Year EndedDecember 31,(In thousands, except per share data)2012201120122011(unaudited)  (unaudited)Revenues:Collaborative research

$
218$
320$
783$
,632Subscription and license fees

-23306217Total revenues

2183431,0891,849Operating expenses:Research and development, including stock-based compensation

of $798, $769, $3,673 and $3,249, respectively

20,99028,10782,57491,828Increase (decrease) in fair value of Symphony Icon, Inc
purchase liability

(200)1,5689,8876,766General and administrative, including stock-based compensation

of $792, $584, $2,822 and $2,458, respectively

3,9204,01017,04317,350Total operating expenses

24,71033,685109,504115,944Loss from operations

(24,492)(33,342)(108,415)(114,095)Interest income

5540213255I
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon To Present At The BIO CEO & Investor Conference
2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
4. Lexicon to Provide Third Quarter 2012 Financial Results
5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
9. Lexicon to Provide Second Quarter 2012 Financial Results
10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- Based on its recent analysis of the breast imaging solutions ... North American Frost & Sullivan Award for Technology Innovation Leadership. ... solutions for the early detection of breast cancer. Over the ... solutions and has expanded its global reach to cover ... , Asia and Australia ...
(Date:8/26/2014)... 26, 2014 Novira Therapeutics, Inc., a privately ... of chronic hepatitis B virus (HBV) infection, today announced ... appointed the Chair of its Scientific Advisory Board (SAB). ... Senior Advisor to the Company.  "We ... Chair," said Christian Schade , Chief Executive Officer ...
(Date:8/26/2014)... 2014  Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.22 per share will ... of record as of the close of business on September ... of the Board of Directors and may be adjusted as ...
Breaking Medicine Technology:Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 2Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 3Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 4Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 5Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 3Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 4
... Calif., Dec. 6 DURECT Corporation,(Nasdaq: ... Phase III trial for Remoxy,had successfully met ... by the U.S. Food and Drug Administration ... an investigational drug based on,DURECT,s patented ORADUR(TM) ...
... Colo., Dec. 5 Replidyne, Inc.,(Nasdaq: RDYN ) ... Collins will participate on the New and Powerful Anti-infectives,panel ... panel,discussion will take place at 11:00 am ET on ... New York City., A live audio webcast of ...
Cached Medicine Technology:Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 4
(Date:8/27/2014)... 2014 AvePoint, the ... software solutions for next-generation social collaboration platforms, announced ... 500|5000, an exclusive ranking of the nation’s fastest-growing ... joins brands such as Alex and Ani, Gazelle, ... , This underscores continued growth and expansion for ...
(Date:8/27/2014)... 27, 2014 Discover Leadership Training is ... corporate transformation through their comprehensive leadership programs. As the ... unparalleled experience in the realm of outcome-focused and benefit-driven ... in a new webinar series titled, “A Women’s Guide ... first of this two part webinar is titled, “My ...
(Date:8/27/2014)... is one of the most loved online bamboo product suppliers; ... now. Recently, it has announced its new selection of ... strives to offer one-stop shopping solutions for people who want ... it is providing big discounts for all the brand new ... a discounted price (up to 30% off) before the deadline ...
(Date:8/27/2014)... Overcoming a turbulent past which branded KC Armstrong as ... Radio Network, WRNW1, has recently signed a multi-million dollar contract ... the WRNW1 family. KC states, “it is such a great ... After KC Armstrong publicly announced his appreciation to Howard Stern, ... “Howard 100 News,” have decided to pay it forward. , ...
(Date:8/27/2014)... 27, 2014 AttorneyOne.com, a recognized authority ... latest information from the FDA on Organic Raw ... 1, that Organic Raw Carob Powder sold from March ... due to possible contamination with Salmonella. , Salmonella ... immune systems. In healthy people it can cause abdominal ...
Breaking Medicine News(10 mins):Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 2Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 3Health News:Barb Moses, Vice President of Discover Leadership Training, Announces New Webinar Titled, “A Women’s Guide to Making Her Life Story a Bestseller” 2Health News:Brand New Bamboo Plywoods Now Offered At BambooIndustry.com 2Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:Organic Raw Carob Powder by Sunburst SuperFoods Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... The Songs of Love ... uplifting, personalized songs for children and teens struggling with a life-threatening ... professionally produced with lyrics containing the child,s name and references to ... Songs are written and performed in the musical style that the ...
... improved hearing and alleviated other symptoms in patients with ... appear in the July 23 New England Journal ... researchers from Massachusetts General Hospital (MGH) report that bevacizumab ... of NF2 patients, the first reported successful NF2 treatment ...
... The world-wide explosion of overweight people has been called ... recognized. Could it really be an epidemic involving an ... increasing prevalence of overweight conditions in our society, investigators ... as a potential direct contributor to obesity. ...
... WASHINGTON, July 8 The results of a study published ... Journal (BMJ) support the findings of a white paper released ... (SCHS) regarding the potentially lifesaving qualities of cholesterol lowering drugs ... "In patients without established cardiovascular disease but with cardiovascular risk ...
... , TROIS-RIVIERES, Quebec, July 8 The Narconon drug rehab ... involved with drug related charges due to their addiction. ... a drug addiction, and just one day gets caught by ... a representative of Narconon Trois-Rivieres. "This is an all ...
... July 8 On the heels of a new campaign launched ... to unsightly "canckles," Dr. Marc Mittleman, founder and director of ... clubs and their members to focus on a real health issue ... in warm, moist environments like locker rooms, communal showers, pool and ...
Cached Medicine News:Health News:Donate Your Car to the Songs of Love Car Donation Program 2Health News:Anti-angiogenesis treatment improves hearing in some NF2 patients 2Health News:Anti-angiogenesis treatment improves hearing in some NF2 patients 3Health News:British Medical Journal Report Supports SCHS White Paper on Statins 2Health News:Drug Crimes in Canada Cause Continuing Problems for Small Communities 2Health News:While Health Clubs Say No to 'Canckles,' Leading Podiatrists Say No to Toenail Fungus 2Health News:While Health Clubs Say No to 'Canckles,' Leading Podiatrists Say No to Toenail Fungus 3
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: